Search hospitals > Illinois > Springfield
Southern Illinois University School of Medicine
Claim this profileSpringfield, Illinois 62702
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Relapse
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Lung Cancer
585 reported clinical trials
11 medical researchers
Summary
Southern Illinois University School of Medicine is a medical facility located in Springfield, Illinois. This center is recognized for care of Parotid Gland Cancer, Cancer, Relapse, Adult T-Cell Leukemia/Lymphoma, Lung Cancer and other specialties. Southern Illinois University School of Medicine is involved with conducting 585 clinical trials across 825 conditions. There are 11 research doctors associated with this hospital, such as Bryan A. Faller, Gregory P. Brandt, James L. Wade, and Jeffrey Bennett, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cancer
239 reported clinical trials
296 drugs studied
Gregory P. BrandtSouthern Illinois University School of Medicine8 years of reported clinical research
Expert in Cancer
Expert in Lymphoma
40 reported clinical trials
85 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Relapse
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Jeffrey Bennett, MDSouthern Illinois University School of Medicine5 years of reported clinical research
Studies Depression Treatment
Studies Depression
3 reported clinical trials
5 drugs studied
Clinical Trials running at Southern Illinois University School of Medicine
Lung Cancer
Breast Cancer
Parotid Gland Cancer
Breast cancer
Kidney Cancer
Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Prostate Cancer
Ovarian Cancer
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Southern Illinois University School of Medicine?
Where is Southern Illinois University School of Medicine located?
Who should I call to ask about financial aid or insurance network?
What insurance does Southern Illinois University School of Medicine accept?
What awards or recognition has Southern Illinois University School of Medicine received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.